Patients Are Concerned About Developing an Opioid Addiction Following Mohs Microscopic Surgery
August 1st 2023Patients about to undergo Mohs microscopic surgery reported that they were more likely to request over-the-counter medications if they perceived their risk of opioid addiction to be high.
Quizartinib Plus Chemo Gains FDA Approval for Newly Diagnosed, FLT3-ITD+ AML
July 21st 2023Quizartinib has been approved by the FDA for use with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy after consolidation chemotherapy, to treat adults with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive, as detected by an FDA-approved test.
Trastuzumab Deruxtecan Elicits Durable Response in HER2+ Gastric/GEJ Cancer
July 19th 2023Trastuzumab deruxtecan elicited a confirmed objective response rate of 42% in patients with HER2-positive gastric or gastroesophageal junction cancer, according to findings from the phase 2 DESTINY-Gastric02 trial.
Delayed HRQOL Outcomes Are Observed With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
July 18th 2023The onset of skeletal events and events that affect health-related quality of life were delayed with the addition of lutetium Lu 177 vipivotide tetraxetan to standard of care for patients with metastatic castration-resistant prostate cancer.